CORDIS
EU research results

CORDIS

English EN

Innovative medicines for europe

Objective

The discovery and development of new drugs is very costly and attrition rates are high. Initiatives to reduce the rate of attrition during later phases are clearly desirable and if successfully implemented will reduce development costs. The InnoMed proposal addresses the complex issues associated with the future of biomédical research in the EU, and addresses ways of achieving accelerated development of, safe and more effective medicines, aiming to revitalize the European biopharmaceutical research environment. InnoMed's wide consortium base, being led by the European Federation of Pharmaceutical Industry and Associations (EFPIA), guarantee's a commitment from all the stakeholders needed to change the process of drug development in Europe. The course for addressing the necessary changes is to first develop a Strategic Research Agenda (SRA) that will encompass the whole path from discovery of a new drug target to the validation and approval stages of a new drug compound. This will be agreed by all the relevant stakeholders via meetings and workshops. Four key bottlenecks in the drug development process will be addressed: Safety Efficacy Knowledge Management Training and Education This comprehensive strategy with a detailed roadmap will lead to the deployment of a European Technology Platform (ETP). This European Technology Platform will deliver added value to the drug discovery and development process and to individual stakeholders. To ensure the relevance of the ETP InnoMed will validate it using two research proposals, AddNeuroMed, which will develop and validate novel surrogate markers based upon in vitro and in vivo models in animals and humans, using Alzheimer's disease as a testing platform. PredTox will deliver new biomarkers of toxicity and a greater understanding of mechanisms of toxicity. Both of these projects will demonstrate the viability and necessity of the ETP.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES AND ASSOCIATIONS

Address

Rue Du TrÔNe 108
Brussels

Belgium

Administrative Contact

Marie-claire PICKAERT (Ms.)

Participants (41)

Sort alphabetically

Expand all

F. HOFFMANN-LA ROCHE LTD

Switzerland

BOEHRINGER INGELHEIM GMBH

Germany

EUROPEAN FEDERATION OF BIOTECHNOLOGY

Belgium

INSTITUT DE RECHERCHES INTERNATIONALES SERVIER

France

ELI LILLY AND COMPANY

United States

MERCK KGAA

Germany

NOVO NORDISK A/S

Denmark

PHARMIDEX PHARMACEUTICAL SERVICES LIMITED

United Kingdom

JULIUS-MAXIMILLIAMS-UNIVERSITAET WUERZBURG

Germany

CAPSANT NEUROTECHNOLOGIES LTD

United Kingdom

UNIVERSITY OF KUOPIO

Finland

UNIVERSITA DEGLI STUDI DI PERUGIA

Italy

ARISTOTLE UNIVERSITY OF THESSALONIKI

Greece

ROSKILDE UNIVERSITETSCENTER

Denmark

ASTRAZENECA AB

Sweden

KUNGLIGA TEKNISKA HOEGSKOLAN

Sweden

KAROLINSKA INSTITUTET

Sweden

NOVARTIS PHARMA AG

Switzerland

N.V. ORGANON

Netherlands

GENEDATA AG

Switzerland

KING'S COLLEGE, LONDON

United Kingdom

ISTITUTO DI RICERCHE BIOMEDICHE "A. MARXER" RBM SPA

Italy

CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE

France

GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD

United Kingdom

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

Ireland

PROTEOME SCIENCES PLC

United Kingdom

HACETTEPE UNIVERSITESI

Turkey

UNIVERSITY COLLEGE LONDON

United Kingdom

UNIVERSITY OF SOUTHAMPTON

United Kingdom

HUNTER FLEMING LIMITED

United Kingdom

SANOFI-AVENTIS DEUTSCHLAND GMBH

Germany

ARTTIC IN BRUSSELS SPRL

Belgium

JANSSEN PHARMACEUTICA N.V

Belgium

BIOWISDOM LIMITED

United Kingdom

CEREBRICON LTD.

Finland

EUROPEAN FEDERATION FOR PHARMACEUTICAL SCIENCES

Sweden

DEPARTMENT OF OLD AGE PSYCHIATRY & PSYCHOTIC DISORDERS, MEDICAL UNIVERSITY OF LODZ

Poland

CIPHERGEN BIOSYSTEMS, INC.

United States

NYCOMED GMBH

Germany

AVENTIS PHARMA RECHERCHE-DÉVELOPPEMENT

France

BAYER PHARMA AG

Germany

Project information

Grant agreement ID: 518170

  • Start date

    1 October 2005

  • End date

    31 January 2009

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 18 532 646

  • EU contribution

    € 11 998 527

Coordinated by:

EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES AND ASSOCIATIONS

Belgium